Jason Parish is a member of the firm’s Litigation section and focuses his practice on complex litigation and government investigations. He has appeared before federal and state courts across the country and has taken numerous cases to trial.
Jason has significant experience with issues facing the healthcare and life sciences industries and is the co-head of Buchanan’s life sciences group. For the last several years, Jason has represented several generic drug companies in the nationwide Average Wholesale Price litigation. He coordinated the defense of dozens of lawsuits in federal and state courts across the country, including qui tam actions under the federal False Claims Act and civil enforcement actions by state attorneys general under state consumer protection, false claims, and false advertising statutes.
Jason frequently represents healthcare and life sciences companies in complex disputes. In the last several years, his practice has included representation of brand and generic drug companies in reverse payment settlement litigation, product liability matters, antitrust matters, and a wide range of contract and commercial disputes. Jason currently represents a generic drug company in multi-district litigation in which plaintiffs allege an industry-wide conspiracy to fix generic drug prices.
Prior to joining Buchanan, Jason was a partner at Kirkland & Ellis LLP where he represented numerous clients in high-stakes, ‘bet the company’ matters. Jason was counsel to BP in government investigations and litigation related to the 2010 Deepwater Horizon disaster, to Volkswagen Group of America in government investigations related to the company’s alleged use of software to defeat government emissions tests, and to Allergan in the nationwide opioid litigation.
Jason’s experience spans antitrust, consumer protection, False Claims Act, products liability, and employment matters. He also has counseled numerous clients through government investigations, including inquiries by DOJ, FTC, HHS OIG, CMS, state attorneys general and Congress.
While many companies shifted to a remote workforce after the COVID-19 outbreak, this did not necessarily result in a slowdown in investigations. At the time, government agencies in fact cautioned companies not to let down their guard in conducting in...